Immunotherapy toxicities. Dr Fiona Taylor
|
|
- Oliver McKinney
- 5 years ago
- Views:
Transcription
1 Immunotherapy toxicities Dr Fiona Taylor
2 Outline Understand toxicities Anticipate toxicities Key steps to safely using and achieving the most benefits from immunotherapies for patients Manage toxicities
3 Immunotherapies are novel agents Increasing use NICE/CDF approved Clinical Trials Therefore more likely to encounter patients with immunotherapy toxicities On the wards, in clinics, calling the hotline Toxicities may become more complicated Combination with chemotherapy, radiotherapy and other immunotherapies
4 Patient assessment How are you going to assess a patient commencing immunotherapy?
5 Baseline assessment Clinical PS 0 or 1 or 2 Co-morbidities Medications Autoimmune diseases 7.5mg prednisolone, potential drug interactions Bloods FBC U+E LFTs Blood borne viruses Quantiferon test Baseline hormone/endocrine profile HIV, Hep B and C active or latent TB FSH, LH, oestradiol/testosterone prolactin 9am cortisol, ACTH TSH, free T4 glucose, IGF-1 (Additional bloods for combination immunotherapy Amylase, lipase)
6 Toxicities
7 Outline Understand toxicities Anticipate toxicities Key steps to safely using and achieving the most benefits from immunotherapies for patients Manage toxicities
8 How common are toxicities? Immune related adverse events (IrAE) occur in up to 90% patients administered ipilimumab up to 70% patients administered PD1/PDL1 inhibitors (pembrolizumab, nivolumab, atezolizumab) First line pembrolizumab (PD1) in lung cancer 1 in 10 had a G3 or G4 toxicity (better than chemotherapy) 1 in 20 stopped treatment due to toxicity
9 Why do toxicities develop? Immunotherapies work to activate the immune system against cancer Toxicities occur because the immune system attacks self Results in inflammation and dysfunction Hence tend to exclude patients with pre-exisiting autoimmune conditions where there is already a condition present that attacks self
10 There is a broad spectrum of potential toxicities Just about every part of the body! S. Champiat et al. Ann Oncol 2016;27:
11 What might the patient complain of? LUNGS BOWEL AND STOMACH LIVER KIDNEYS HORMONE PRODUCING GLANDs HEART MUSCLES SKIN OTHER SOB, cough Diarrhoea (watery, loose or soft stool), blood or mucous in stool, pain or tenderness stomach area or abdomen Yellow eyes, pain right sided of stomach area, tiredness, nausea Decreased urine output Headaches, blurring or double vision, fatigue, weight changes, behavioural changes (loss of libido, forgetfulness, irritability) Chest pain, irregular heart beat, palpitations Muscle pain, stiffness, confusion, fatigue Rash, itch, skin blistering, skin peeling, ulcers, dry skin Eye pain, redness, blurred vision, decreased appetite, nausea/vomiting Tingling, numbness arms and legs, fever, seizures, weakness and drowsiness
12 There is a broad spectrum of potential toxicities Just about every part of the body! S. Champiat et al. Ann Oncol 2016;27:
13 Pembrolizumab alone PD1 Nivolumab alone PD1 Ipilimumab alone CTLA4 COMBINATION (ipi and nivo) Immune related adverse events in advanced melanoma
14 Toxicity in melanoma COMBINATION (ipi and nivo) Nivolumab alone PD1 Ipilimumab alone CTLA4 68.8% of patients who discontinued the combination therapy due to toxicity achieved either complete or partial response Larkin et al. The New England Journal of Medicine Issue: Volume 373(1), 2 July 2015, p 23 34
15 Toxicity patterns - Ipilimumab
16 Fusi, ESMO immunotherapy preceptorship 2015 Hypothyroidism
17 Outline Understand toxicities Anticipate toxicities Key steps to safely using and achieving the most benefits from immunotherapies for patients Manage toxicities
18 How do we treat immune-mediated toxicities? Suppress the immune system Aiming to suppress the body's reaction against self Steroids Oral prednisolone IV methylprednisolone Steroid sparing agents Infliximab Mycophenylate Tacrolimus and cyclosporin Supportive measures Monitor response
19 General principles for managing toxicities Understand and Anticipate Education, education, education! Critical role of staff to educate patients and colleagues Management Early assessment and intervention (initiation of steroids if grade 2 or above) is key Exclude non-immunotherapy causes Think of rarer toxicities (pituitary failure, GBS) Multi-disciplinary approach early involvement of specialists Algorithms are available: use them Monitor closely Consider further immunosuppressive agent if symptoms don t start to resolve within 2-3 days (infliximab, mycophenylate) Taper steroids slowly when symptoms back to grade 1 or less (usually over a month)
20 STH General Algorithm CTCAE for grading
21
22
23
24 Specific toxicities Colitis Hepatitis Pneumonitis Rash Endocrine Neurological
25 Colitis Early treatment is key Severe and potentially fatal immune-mediated colitis seen in 7% patients on ipilimumab Patients may present with: Diarrhoea Blood or mucus in stool +/-fever Abdominal pain Signs of bowel perforation or ileus
26 Diarrhoea/Colitis
27 Typical presents with raised liver enzymes Laboratory abnormalities eg elevations in LFTs (AST/ALT, total bilirubin) May develop without clinical symptoms Exclude other causes Hepatitis Life-threatening hepatitis develops in 1% patients
28 Hepatitis
29 Pneumonitis Uncommon (monotherapy 5% lung, renal, 2% melanoma) (combination 5-10%) Median onset 3 months (1-19 months) Symptoms/signs include breathlessness, cough, haemoptysis & hypoxia Investigations CXR Sputum sample HRCT: ground glass opacities, may look like ARDS/non specific pneumonias Consider referral to respiratory and bronchoscopy
30 Pnemonitis
31 Skin Toxicities Common 30-50% Range of presentations Maculopapular rash 39% with pembro, 21% with ipi Vitiligo 10% with pembro, 2% with ipi Remember sun protection Follicular/urticarial dermatitis Mucositis Sweet s syndrome (acute febrile neutrophilic dermatosis) Bullous pemphigoid
32 Skin toxicity
33 Endocrinopathies Usually irreversible 4% incidence of severe to life-threatening endocrinopathies: Hypopituitarism, adrenal insufficiency, hyper- or hypothyroidism Common signs and symptoms: Often vague Fatigue Mental status changes/ behavioral changes Unusual bowel habits Headache Abdominal Pain Hypotension/dizzyness Abnormal thyroid function tests and/or serum chemistries
34 Thyroid dysfunction More common with anti-pd1 agents (pembro, nivo) 4-10% Grade 3 or 4 toxicities rare Hypothyroidism TSH >10 mu/l Free T4 <12 pmoll Hyperthyroidism TSH <0.4 mu/l Free T4 >22 pmol/l
35 Hypopituitarism Combination 8% Ipi 4% PDL1 <1% Commonly 6-13 weeks (up to 19 months) Vague symptoms- fatigue, arthralgia, behavioural changes Specific symptoms-headache, visual changes, dizziness, nausea
36 Hypoadrenalism Likely if 9am cortisol <100 and possible if Vague symptoms Specific symptoms dizzyness/collapse, nausea vomiting
37 Neurological Toxicity Rare but can be irreversible 1% incidence of serious and fatal immune-mediated neurological adverse reactions: Sensory and motor neuropathy Guillain-Barré syndrome Myasthenia gravis Early recognition and treatment are critical Need to distinguish from non-drug related causes (eg, cancer, infection, stroke) Presentation: Unilateral or bilateral muscle weakness, sensory alterations, and paresthesia.
38 Neurological toxicity
39 Larkin J, ESMO preceptorship presentation 2015
40 S. Champiat et al. Ann Oncol 2016;27:
41 Steroid tapering Length of tapering depends on severity of side effect Need close monitoring as risk of recurrence of toxicity PPI cover (lansoprazole) Oral steroids Taper over 4-6 weeks Reduce prednisolone 10mg every 3 days (as toxicity allows) until dose is 10mg/day then reduce by 5mg every 5 days and stop IV steroids Taper over at least 6 weeks Reduce prednisolone 10mg every 5-7 days (as toxicity allows) until dose is 10mg/kg then reduce by 5mg every 5 days and stop
42 Potential steroid side effects Hyperglycaemia Monitor random BMs afternoon Insomnia Infection PCP prophylaxis (co-trimoxazole Mon/Wed/Fri) (>4 weeks 25mg pred) Oral thrush Osteoporosis Check Vitamin D and calcium consider bisphosphonate if on steroids for >3months
43 How are you going to assess a patient for immunotherapy toxicities?
44 Immunotherapy toxicity assessment Clinical history +/- examination Skin Rash, itch, examine GI Diarrhoea, abdominal pain, nausea, vomiting Neurological Loss of sensation,weakness,p+n, behavioural change Endocrine tiredness, nausea, dizzyness, postural BP drop Fatigue Blood tests Liver Function Tests Endocrine profile Renal profile FBC
45 Case Studies
46 Case 1 57 year old female BRAF WT metastatic melanoma (lung metastases) June 2016: commenced pembrolizumab August 2016: CT imaging after 4 cycles stable disease September 2016: seen in clinic for cycle 5 clinically very well
47 What are you going to do?
48 Exclude other causes Supportive measures Monitor GRADE ASSESSMENT MANAGEMENT FOLLOW UP
49 Admitted, commenced on 2mg/kg IV methylprednisolone No more pembrolizumab possible Proceeded to join a clinical trial upon disease progression
50 Case 2 49 year old male BRAF WT metastatic melanoma (brain & lung mets) Diagnosed 2011, had surgical excision of brain mets, followed by post-op whole brain RT Commenced on Temozolomide, stopped after 2 cycles due to disease progression Commenced on Ipilimumab late 2011 Diarrhoea 8 times in the last 24 hours after 3 cycles
51 What are you going to do?
52 GRADE ASSESSMENT MANAGEMENT Needed steroids and infliximab Ipilimumab stopped Exclude other causes Supportive measures Monitor
53 Developed white forelock Eventually stopped having scans Got driving licence back Remains alive and well, last seen in clinic 2018(aprox 8 years)
54 Case 3 55 year old male T4N3M1b (bone) squamous cell lung cancer Admitted with increased SOB following 1 cycle of pembrolizumab Sats 80% air, RR 30/min Pyrexial 39 Pulse 120 bpm
55 What are you going to do?
56 Exclude other causes Supportive measures Monitor GRADE ASSESSMENT MANAGEMENT
57 In hospital on 15L Oxygen 2 months later
58 Case 4 52 year old male with metastatic melanoma BRAF WT 3 rd cycle of ipilimumab and nivolumab 3 weeks ago Attended WAU due to pyrexia and found to have a postural blood pressure drop Cortisol 15 TSH <0.02, free T (hyperthyroid) LSH <0.1 ( ), FSH 2.4 (1.5-12), testosterone <0.4 ( ) Prolactin 25 (86-324)
59
60 Bulky pituitary on MRI for a man of age 52 with heterogenous uptake post IV contrast
61 Endocrinology involvement Hydrocortisone 20mg tds (IM or IV if not eating or drinking) MRI pituitary gland Oral prednisolone 1mg/kg once a day
62 Sequence of events 7 th June cortisol >500, TSH <0.12 Seen in WAU 2 weeks ago with a headache- sent home Calls hot line 1 week ago to inform them his BP is low 83 systolic, asked to get GP to check. BP by GP > 90 and noted that he had a bit of a postural drop no other action taken Day before pre-assesment for 4 th cycle called hot line as temp >38 o C Seen in WAU was noted to have a significant postural BP drop. Cortisol 15
63 Please note Some patients will still think that they are on chemotherapy- get the names of the drugs Symptoms of side effects can be subtle, may appear mild but can worsen if left untreated Alarm bells must ring when patients are on combination treatment as the chance of a G3/G4 toxicity is 1 in 2 Signs/symptoms can be delayed and may occur weeks to months after last injection (cf chemotherapy < 6 weeks)
64 Summary Increasing use of immunotherapy agents means that more patients will present to hospital with toxicities Toxicities occur due to over activation of the immune system against self Early assessment and recognition is vital Treatment of toxicities is with immunosuppressant agents Steroids Steroid sparing agents Need to monitor response as patients can relapse Less likely but toxicities can still occur months later
65 HOW TO FIND THE GUIDELINES Thanks for listening any questions? CLINICAL DIRECTORATES AND SPECIALITES ACUTE ONCOLOGY ANTI CANCER DRUG HANDBOOK H_CGP/CancerServices/1_5_1a_Immuno therapy_toxicity_guidelines_v1.docx
Nursing Perspective on iraes: Patient Education, Monitoring and Management
Nursing Perspective on iraes: Patient Education, Monitoring and Management Rebecca Lewis, CRNP Nurse Practitioner University of Pittsburgh-HCC Shadyside Disclosures No relevant financial relationships
More informationMelanoma Immunotherapy. Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management
Melanoma Immunotherapy Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management Mike Buljan, NP UCSF Medical Center Melanoma Oncology Disclosures None Only FDA-approved
More informationOPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS Alberto Fusi Charité Comprehensive Cancer Centre Berlin, Germany 1 Immune check point blockade with CTLA-4, anti-pd-1
More informationAtezolizumab Non-small cell lung cancer
Systemic Anti Cancer Treatment Protocol Atezolizumab Non-small cell lung cancer PROTOCOL REF: MPHAATNSCLC (Version No: 1.0) Approved for use in: Locally advanced/metastatic non squamous or squamous non-small
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationSummary of the risk management plan (RMP) for Opdivo (nivolumab)
EMA/285771/2015 Summary of the risk management plan (RMP) for Opdivo (nivolumab) This is a summary of the risk management plan (RMP) for Opdivo, which details the measures to be taken in order to ensure
More informationIpilimumab in Melanoma
Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or
More informationImmunotherapy: Toxicity Management. Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital
Immunotherapy: Toxicity Management Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital Disclosures Honoraria and travel support from BMS, MSD, Novartis Advisory board for MSD
More informationPEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate Day 1 Pembrolizumab 2mg/kg IV Infusion 100mL 0.9% Sodium Chloride* Or 100mL 5% Glucose* *Final concentration must be between 1 to 10mg/mL Over
More informationNivolumab and Ipilimumab
Nivolumab and Ipilimumab Indication Advanced (unresectable or metastatic) melanoma. (NICE TA400) ICD-10 codes Codes prefixed with C43 Regimen details Cycles 1-4 Nivolumab and Ipilimumab every 3 weeks Day
More informationFor the Patient: USMAVFIPI
For the Patient: USMAVFIPI Other Names: First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced F =
More informationFor the Patient: USMAVNIV
For the Patient: USMAVNIV Other Names: Treatment of Unresectable or Metastatic Melanoma Using Nivolumab U = Undesignated (requires special approval) SM = Skin and Melanoma AV = AdVanced NIV = NIVolumab
More informationFor the Patient: USMAVPEM
For the Patient: USMAVPEM Other Names: Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced PEM = Pembrolizumab
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor
Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor TECENTRIQ DISCUSSION SUPPORT What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationCheckpoint inhibitors: Strategies to checkmate T-cell mediated toxicity. Disclosure Statement. Learning Objectives
Checkpoint inhibitors: Strategies to checkmate T-cell mediated toxicity Adam J. DiPippo, PharmD Clinical Pharmacy Specialist Leukemia Texas Society of Health-System Pharmacists 2017 Annual Seminar April
More informationATEZOLIZUMAB (TECENTRIQ )
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationManaging immune related toxicity. Karijn Suijkerbuijk May 27 th 2017
Managing immune related toxicity Karijn Suijkerbuijk May 27 th 2017 Disclosures Advisory role: BMS, Merck Travel support: Amgen, Novartis, Roche Whybother? Patients are dying from toxicity Eggermont ipilimumab
More informationATEZOLIZUMAB (TECENTRIQ ) in urothelial carcinoma
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationSummary of the risk management plan (RMP) for Nivolumab BMS (nivolumab)
EMA/359171/2015 Summary of the risk management plan (RMP) for Nivolumab BMS (nivolumab) This is a summary of the risk management plan (RMP) for Nivolumab BMS, which details the measures to be taken in
More informationFor the Patient: ULUAVPMB
For the Patient: ULUAVPMB Other Names: Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab U = Undesignated (requires special approval) LU = LUng AV = AdVanced PMB = PeMBrolizumab ABOUT
More informationBCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab
BCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab Protocol Code Tumour Group Contact Physician USMAVNIV Skin and Melanoma Dr. Kerry Savage ELIGIBILITY: Unresectable
More informationImmunotherapy. Immunotherapy Triage
Immunotherapy Immunotherapy Triage The most commonly used drug is Ipilimumab for Metastatic Melanoma, but use of immunotherapy is developing in lung cancer and in clinical trials. Drugs include Nivolumab
More informationNivolumab. Nivolumab
Nivolumab Nivolumab This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary: for some people immunotherapy may reduce the risk of the cancer coming back, for
More informationToxicity of Systemic Melanoma Therapies. Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney
Toxicity of Systemic Melanoma Therapies Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney Disclosures Advisory Board Novartis, BMS, Sanofi, Pfizer Travel support
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationImmune-Related Adverse Reaction (irar) Management Guide
REGIMEN Immune-Related Adverse Reaction (irar) Management Guide OPDIVO as monotherapy is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) with progression
More informationBC Cancer Protocol Summary for Treatment of Advanced Non- Small Cell Lung Cancer Using Pembrolizumab
BC Cancer Protocol Summary for Treatment of Advanced Non- Small Cell Lung Cancer Using Pembrolizumab Protocol Code Tumour Group Contact Physician ULUAVPMB Lung Dr. Christopher Lee ELIGIBILITY: Advanced
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team
Discussing TECENTRIQ (atezolizumab) with your healthcare team What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: a type of lung cancer called non-small cell lung cancer (NSCLC). TECENTRIQ
More informationPreparing for Your Immune Checkpoint Inhibitor (CPI) Treatment
Preparing for Your Immune Checkpoint Inhibitor (CPI) Treatment Overview What is the immune system? What are immune checkpoint inhibitors? What are the side effects to look out for? How are side effects
More informationToxicity from Checkpoint Inhibitors. James Larkin FRCP PhD
Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech
More informationHealthcare Professional. Frequently Asked. Questions. Brochure
YERVOY (ipilimumab) Healthcare Professional Frequently Asked Questions Brochure YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. 1 This medicinal product
More informationManaging Checkpoint Inhibitor Toxicities. Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute
Managing Checkpoint Inhibitor Toxicities Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute Approved Indications Ipilimumab Nivolumab Pembrolizumab* Atezolizumab Avelumab Durvalumab Ipi + Nivol
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr OPDIVO is used to treat: Adults with skin cancer (advanced melanoma) who have not been treated and who have specific
More informationImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Jeryl Villadolid
More informationComplications of Immunotherapy
Complications of Immunotherapy Sarah Norskog, PharmD, BCOP Oncology Pharmacy Specialist University of Colorado Hospital Disclosures I have no relevant financial relationships with commercial interests
More informationWARNINGS AND PRECAUTIONS - COMBINATION OF OPDIVO AND YERVOY
OPDIVO (op-dee-voh) Nivolumab (nee-vol-u-mab) Consumer Medicine Information WARNINGS AND PRECAUTIONS - COMBINATION OF OPDIVO AND YERVOY Both OPDIVO and Yervoy act on your immune system and may cause inflammation
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
Nivolumab (Opdivo ) for treatment of advanced melanoma and Renal Cell Cancer (Also advanced/ metastatic NSCLC EMAS patients only -Nov 2016) DRUG ADMINISTRATION SCHEDULE (SINGLE AGENT Day Drug Daily dose
More informationYou should read this leaflet carefully and keep it in a safe place to refer to it later. WHAT IS OPDIVO USED FOR
(op-dee-voh) Nivolumab (nee-vol-u-mab) Consumer Medicine Information WARNINGS AND PRECAUTIONS - COMBINATION OF AND YERVOY Both and Yervoy act on your immune system and may cause inflammation in parts of
More informationSafety Immune Related Adverse Events (irae) Focus on NSCLC Aaron Hansen, BSc, MBBS, FRACP
Safety Immune Related Adverse Events (irae) Focus on NSCLC Aaron Hansen, BSc, MBBS, FRACP Division of Medical Oncology and Hematology Bras Drug Development Program Princess Margaret Cancer Centre, Toronto,
More informationYOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC)
YOUR GUIDE TO TECENTRIQ (atezolizumab) For previouslytreated advanced non-small cell lung cancer (NSCLC) ABOUT THIS BOOKLET This booklet is for people with advanced non-small cell lung cancer (NSCLC) who
More informationIpilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy.
Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. (NICE TA268) ICD-10 codes Codes prefixed with C43 Regimen details Day Drug Dose
More informationImportant safety information to minimise the risk of immune-related adverse reactions
Your Guide to KEYTRUDA (pembrolizumab) Important safety information to minimise the risk of immune-related adverse reactions Information for Patients This medicine is subject to additional monitoring.
More informationNivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions
Nivolumab Other Names: Opdivo About this Drug Nivolumab is used to treat cancer. It is given in the vein (IV). Possible Side Effects (More Common) Bone marrow depression. This is a decrease in the number
More informationCANCER IMMUNOTHERAPY. Pocket Guide
CANCER IMMUNOTHERAPY Pocket Guide Unique Clinical Features Tumor Response Kinetics Response patterns associated with immune checkpoint blockade may differ from those associated with conventional therapies,
More informationSummary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO. Avelumab 200 mg/10 ml. Concentrate for Solution for Infusion
Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO Avelumab 200 mg/10 ml Concentrate for Solution for Infusion Marketing Authorisation Number 66380 Marketing Authorisation Holder:
More informationHEY Guidelines for the management of Toxicities associated with immune checkpoint inhibitors.
Hull and East Yorkshire Hospital NHS Trust Queen s centre for Oncology and Haematology Castle Hill Hospital HEY Guidelines for the management of Toxicities associated with immune checkpoint inhibitors.
More informationMANAGEMENT OF IMMUNE-RELATED GI AND LIVER TOXICITY
MANAGEMENT OF IMMUNE-RELATED GI AND LIVER TOXICITY Alberto Fusi Charité Comprehensive Cancer Centre - Berlin St. George s University - London TAO Meeting - Cancer Toxicity Management Paris - 8th-9th December
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More information7.3 Suggested Evaluation and Treatment for Immunerelated Adverse Events Gastrointestinal Tract
7.3 Suggested Evaluation and Treatment for Immunerelated Adverse Events Early diagnosis and treatment intervention for high-grade iraes can help prevent the occurrence of complications, such as GI perforation.
More informationBCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab
BCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab Protocol Code Tumour Group Contact Physician USMAVIPI Skin and Melanoma Dr. Kerry Savage ELIGIBILITY: Unresectable
More informationManagement of Immune Checkpoint Inhibitor Related Toxicities
Management of Immune Checkpoint Inhibitor Related Toxicities Katie Wolfram, PharmD Clinical Pharmacist, Oncology Memorial Hospital of South Bend A Webinar for HealthTrust Members November 12, 2018 Disclosures
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT YERVOY 5 mg/ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains
More informationWHAT IS OPDIVO USED FOR
(op-dee-voh) Nivolumab (nee-vol-u-mab) Consumer Medicine Information WARNINGS AND PRECAUTIONS - COMBINATION OF AND YERVOY IN THE TREATMENT OF ADVANCED MELANOMA Both and Yervoy act on your immune system
More informationMANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS
MANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS John B.A.G. Haanen MD PhD CONTENT OF THIS PRESENTATION General aspects of immune related adverse events related to immune checkpoint
More informationImmune-Mediated Adverse Events Management Handbook
Immune-Mediated Adverse Events Management Handbook Your guide to addressing the immune-mediated adverse events (imaes) associated with patients taking PD-L1 inhibition therapy Indications and Usage IMFINZI
More informationIpilimumab Monotherapy
INDICATIONS FOR USE: Ipilimumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of advanced (unresectable or metastatic) melanoma in adults C43 00105a ODMS *If a reimbursement indicator
More informationTOXICITY RELATED TO IO IN LUNG CANCER
TOXICITY RELATED TO IO IN LUNG CANCER Dr. Jorge A. Alatorre Alexander Head of the Thoracic Oncology Clinic at Instituto Nacional de Enfermedades Respiratorias American British Cowdray Medical Center Mexico
More informationOverview of Immunotherapy Related Adverse Event (irae) Management
Overview of Immunotherapy Related Adverse Event (irae) Management DR. ROLAND LEUNG MEDICAL ONCOLOGY DEPARTMENT OF MEDICINE THE UNIVERSITY OF HONG KONG QUEEN MARY HOSPITAL Outline Immune system overview
More informationENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY
ENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY Lauren Clarine DO, Renil Rodriguez Martinez MD, Matthew Levine MD, Amy Chang MD, and Megan McGarvey MD May 6, 2017 Immune checkpoint inhibitors
More informationBCCA Protocol Summary for Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab
BCCA Protocol Summary for Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab Protocol Code Tumour Group Contact Physician ULUAVNIV Lung Dr. Christopher Lee ELIGIBILITY: Advanced non-small
More informationBCCA Protocol Summary for Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Nivolumab
BCCA Protocol Summary for Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Nivolumab Protocol Code Tumour Group Contact Physician UGUAVNIV Genitourinary Dr. C. Kollmannsberger ELIGIBILITY:
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion Read this carefully before you start
More informationNivolumab Ipilimumab Combination Therapy
INDICATIONS FOR USE: Nivolumab Ipilimumab Combination INDICATION ICD10 Regimen Code *Reimbursement Status Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable
More informationform: Concentrate for solution for infusion. intravenous push or bolus injection. not been previously treated with chemotherapy. Inclusion criteria
Product Name KEYTRUDA Active substance Pembrolizumab Medical Need Program with KEYTRUDA for the First Line treatment of metastatic Non Small Cell Lung Cancer (NSCLC) in adults whose tumors express PD L1
More informationUMN request : information to be made public Page 1
Product Name KEYTRUDA Active substance Pembrolizumab MK 3475 Indication and conditions of use Keytruda for the treatment of unresectable or metastatic melanoma patients in first line therapy (or after
More informationUnderstanding your treatment and the side effects you may experience
Understanding your treatment and the side effects you may experience What does treat? is a prescription medicine used in combination with YERVOY to treat a type of skin cancer called melanoma that has
More informationPast Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1
Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma
More informationCancer Immunotherapy: Promises and Challenges. Disclosures
Cancer Immunotherapy: Promises and Challenges David B. Page, MD Medical Oncology PMG East Hematology & Oncology Earle A. Chiles Research Institute Portland, Oregon Disclosures Consulting: Celldex, Nektar,
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationNivolumab Monotherapy 240mg -14 days
Nivolumab Monotherapy 240mg -14 days This regimen supercedes NCCP Regimen 00349 Nivolumab Monotherapy as of May 2018 due to a change in the licensed dosing posology. INDICATIONS FOR USE: INDICATION ICD10
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION KEYTRUDA has been issued marketing authorization with conditions for the following patients, pending the results of
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion, 20 mg/ml Professed Standard Antineoplastic
More informationYERVOY (yure-voy) Ipilimumab (ipi-lim-u-mab)
YERVOY (yure-voy) Ipilimumab (ipi-lim-u-mab) Consumer Medicine Information WARNINGS AND PRECAUTIONS Yervoy acts on your immune system and may cause inflammation in parts of your body. Inflammation may
More informationAUTOIMMUNE DISORDERS IN THE ACUTE SETTING
AUTOIMMUNE DISORDERS IN THE ACUTE SETTING Diagnosis and Treatment Goals Aimee Borazanci, MD BNI Neuroimmunology Objectives Give an update on the causes for admission, clinical features, and outcomes of
More informationJ. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health
J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health Patient Clinical Information Questionnaire 1.0 Date of Questionnaire Completion; / / 2.0 Patient Data 2.1 Name:
More informationManaging Adverse Events Associated with Immuno-oncologic Agents
Managing Adverse Events Associated with Immuno-oncologic Agents Jennifer Diehl RN, BSN, OCN Cutaneous Oncology Program Moffitt Cancer Center Tampa, FL September 10, 2015 12-1 p.m. EST ICLIO ecourse 05
More informationBristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma
December 2, 2015 Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma (PRINCETON, NJ, November 27, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced that the
More informationProtocol for Hypoadrenalism / Addison s Disease
Protocol for Hypoadrenalism / Addison s Disease Relevance This protocol is relevant to all diagnosing clinicians, ie GPs and Nurses. HCAs and other staff should be aware of the possible presenting symptoms
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationCapital Health Medical Center - Hopewell NEUROSURGICAL-ONCOLOGY Patient History
Capital Health Medical Center - Hopewell NEUROSURGICAL-ONCOLOGY Patient History Please take a few minutes and complete the following questions before you see the doctors so that we may learn a bit more
More informationImmune-related Adverse Events (IrAEs)
West of Scotland Cancer Network Guideline for Management of Immune-related Adverse Events Scope This guidance refers to management of immune-related adverse events caused directly by immunotherapy. Immune-related
More informationGiving appropriate patients another chance to fight OPDIVO
For dmmr/msi-h Colorectal Cancer (CRC) All individuals depicted are models used for illustrative purposes only. Who is OPDIVO for? OPDIVO is a prescription medicine used to treat colorectal cancer (a type
More informationMANAGEMENT OF IMMUNOTHERAPY RELATED GI AND HEPATIC ADVERSE EVENTS
MANAGEMENT OF IMMUNOTHERAPY RELATED GI AND HEPATIC ADVERSE EVENTS Wai K. Leung Li Shu Fan Medical Foundation Professor in Gastroenterology Associate Dean (Human Capital), LKS Faculty of Medicine, University
More informationImmunotherapies. Supporting health professionals to safely care for patients receiving immunotherapy in the cancer setting.
Immunotherapies Supporting health professionals to safely care for patients receiving immunotherapy in the cancer setting. INDEX Select a topic below for more information Principles of immunotherapy Classes
More informationThe most current assessment of this problem can be found in the Apex note dated
Him andpcos Smartphrase:.REFENDOPCOS NOTE: patients with suspected PCOS are welcomed to endocrine clinic. There is also a PCOS clinic is available in the Ob/Gyn Department. I am referring @name@, a @age@
More informationDrug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment
Drug Resistant Tuberculosis Self-reporting of Drugrelated Adverse Events During Treatment Introduction This information has been prepared for people with tuberculosis (TB) that is resistant to the commonly
More informationsystem to help fight cancer Working with your immune
KEYTRUDA Working with your immune system to help fight cancer www.fightcancer.co.nz CONTACT DETAILS Your Oncologist/Specialist Name Phone Phone (after hours) Your Specialist Nurse Name Phone Phone (after
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More information(sunitinib malate) for Kidney Cancer
Sutent (sunitinib malate) for Kidney Cancer Sutent is a medication used to treat adult patients with kidney cancer that has been surgically removed and at high risk of recurrence, or advanced kidney cancer
More informationPackage leaflet: Information for the patient. Bavencio 20 mg/ml concentrate for solution for infusion avelumab
Package leaflet: Information for the patient Bavencio 20 mg/ml concentrate for solution for infusion avelumab This medicine is subject to additional monitoring. This will allow quick identification of
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr OPDIVO nivolumab Intravenous Infusion, 10 mg nivolumab /ml 40 mg and 100 mg single-use vials Antineoplastic Pr OPDIVO has been issued marketing
More informationPatient Intake Form for Allegany Ear, Nose, & Throat
Patient Intake Form for Allegany Ear, se, & Throat Patient Name: What brings you to the office today? Who is your primary care doctor? Please list your current medications: Are you allergic to any medications?
More informationFor males: use effective birth control during your treatment with INLYTA. Talk to your doctor about birth control methods.
PATIENT INFORMATION INLYTA (in-ly-ta) (axitinib) tablets Read this Patient Information before you start taking INLYTA and each time you get a refill. There may be new information. This information does
More information